title: Influence of Chongcao Yigan Capsule on function of intestinal flora and chemoprevention for patients with chronic hepatitis B-induced liver fibrosis.
abstract: OBJECTIVE
  Hapatitis B visus (CHB)-induced fibrosis is a precancerous condition of liver. To explore the influence of Chongcao Preparation (Chongcao Yigan Capsule) on the function of intestinal flora and chemoprevention for patients with CHB-induced liver fibrosis.
  
  
  METHODS
  A total of 136 patients with CHB-induced liver fibrosis were randomly divided into control group treated with lamivudine (LAM) and research group added with Chongcao Yigan Capsule for totally 48 weeks. The changes of intestinal flora, secretory immunoglobin A (SIgA), serum albumin (ALB), prealbumin (PALB), IgA and IgG at different time points in both groups were observed.
  
  
  RESULTS
  Before treatment, there was no significant difference between two groups in each index (P>0.05). After treatment, the intestinal flora were evidently optimized in research group than treatment before (P<0.05 or P<0.01), and were apparently better than those in control group (P<0.05 or P<0.01); SIgA was obviously increased and ALB, PALB, IgA and IgG were markedly improved in research group than treatment before (P<0.05 or P<0.01), and were significantly better than those in control group (P<0.05 or P<0.01).
  
  
  CONCLUSIONS
  Chongcao Yigan Capsule could regulate the intestinal flora, increase SIgA, serum ALB and PALB concentrations and significantly improve serum IgA and IgG as well as strengthen the immunological function and autologous repair capacity of patients with CHB-induced liver fibrosis.
authors.affiliation: Department of Infection, Huai'an Hospital, Nanjing Medical University, Huai'an, China E-mail : chshzh-11@163.com.
authors.forename: Xiao-Hu
authors.initials: XH
authors.lastname: Zhao
authors.forename: Zheng-Yu
authors.initials: ZY
authors.lastname: Cao
authors.forename: Yang
authors.initials: Y
authors.lastname: Shen
authors.forename: Yu-Feng
authors.initials: YF
authors.lastname: Lv
authors.forename: Guang-Rong
authors.initials: GR
authors.lastname: Tao
authors.forename: Sheng
authors.initials: S
authors.lastname: Chen
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D001707:Biopsy, Needle; D002214:Capsules; D018890:Chemoprevention / Q000379:methods; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007150:Immunohistochemistry; D007422:Intestines / Q000187:drug effects* / Q000382:microbiology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy / Q000379:methods; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; C524644:Yi-Gan San